Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW071021 in advanced solid tumors
NCT06882135Phase 1Recruiting
- Sponsor
- Humanwell Healthcare Group Co., Ltd.
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HW071021 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 2 more (2 arms), sponsored by Humanwell Healthcare Group Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 2 years. Started May 2025; status: recruiting.
02
Drugs
HW071021
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)cholangiocarcinoma (CCA)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06882135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882135.